Patent review identifies new FAAH inhibitors, innovative chemical templates, and potential disease models, suggesting therapeutic advancements.
The search for novel and clinically relevant FAAH inhibitors starts with newly disclosed chemical entities. However, reducing translation gaps also requires advances in identifying key biomarkers and developing relevant animal models that mimic target diseases. Additionally, disclosing of innovative chemical templates - including those for allosteric modulation of FAAH - and the identification of suitable and innovative multitarget directed ligands will likely establish FAAH inhibitors as a validated therapeutic option for several diseases.
No takes yet. Share an insight, caveat, or question.
Landolfi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: